Liquid Biopsy for Bile Duct Cancer

No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to test a new blood test that may help doctors detect signs of cancer recurrence or progression in individuals with cholangiocarcinoma, a type of cancer affecting the bile ducts. By analyzing blood samples and medical records, researchers aim to track treatment response and predict future outcomes. The trial seeks participants diagnosed with cholangiocarcinoma who are being considered for surgery to completely remove the cancer. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could enhance future cancer care.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores a new method of monitoring cholangiocarcinoma, a type of bile duct cancer, using liquid biopsy. Unlike traditional treatments that rely heavily on imaging and invasive tissue biopsies to assess treatment response, this approach involves analyzing blood samples to detect cancer markers. This method is less invasive and could potentially provide real-time insights into how well a treatment is working, making it a game-changer in personalizing and improving patient care.

Who Is on the Research Team?

NH

Nguyen H. Tran, MD

Principal Investigator

Mayo Clinic in Rochester

Are You a Good Fit for This Trial?

Inclusion Criteria

I have been diagnosed with cholangiocarcinoma and am being considered for surgery to try to cure it.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Pre-treatment

Collection of blood samples and archived tissue samples for baseline PUMA level assessment

1-2 weeks

Neoadjuvant Treatment

Participants receive neoadjuvant therapy and PUMA levels are monitored pre- and post-treatment

Varies based on treatment protocol

Surgical Intervention

Participants undergo surgical intervention and PUMA levels are assessed pre- and post-surgery

1-2 weeks

Follow-up

Participants are monitored for progression free survival and postoperative survival

Up to 5 years

What Are the Treatments Tested in This Trial?

Interventions

  • Non-Interventional Study

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: ObservationalExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials
3,427
Recruited
3,221,000+